Su Yon Jung1, Jeanette C Papp2, Eric M Sobel2,3, Matteo Pellegrini4, Herbert Yu5, Zuo-Feng Zhang6,7. 1. Translational Sciences Section, Jonsson Comprehensive Cancer Center, School of Nursing, University of California, Los Angeles, Los Angeles, CA, United States. 2. Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States. 3. Department of Computational Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States. 4. Department of Molecular, Cell and Developmental Biology, Life Sciences Division, University of California, Los Angeles, Los Angeles, CA, United States. 5. Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, United States. 6. Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, United States. 7. Center for Human Nutrition, David Geffen School of Medicine, University of California, Los Angeles, CA, United States.
Abstract
BACKGROUND: Immune-related etiologic pathways that influence breast cancer risk are incompletely understood and may be confounded by lifestyles or reverse causality. Using a Mendelian randomization (MR) approach, we investigated the potential causal relationship between genetically elevated C-reactive protein (CRP) concentrations and primary invasive breast cancer risk in postmenopausal women. METHODS: We used individual-level data obtained from 10,179 women, including 537 who developed breast cancer, from the Women's Health Initiative Database for Genotypes and Phenotypes Study, which consists of five genome-wide association (GWA) studies. We examined 61 GWA single-nucleotide polymorphisms (SNPs) previously associated with CRP. We employed weighted/penalized weighted-medians and MR gene-environment interactions that allow instruments' invalidity to some extent and attenuate the heterogeneous estimates of outlying SNPs. RESULTS: In lifestyle-stratification analyses, genetically elevated CRP decreased risk for breast cancer in exogenous estrogen-only, estrogen + progestin, and past oral contraceptive (OC) users, but only among relatively short-term users (<5 years). Estrogen-only users for ≥5 years had more profound CRP-decreased breast cancer risk in dose-response fashion, whereas past OC users for ≥5 years had CRP-increased cancer risk. Also, genetically predicted CRP was strongly associated with increased risk for hormone-receptor positive or human epidermal growth factor receptor-2 negative breast cancer. CONCLUSIONS: Our findings may provide novel evidence on the immune-related molecular pathways linking to breast cancer risk and suggest potential clinical use of CRP to predict the specific cancer subtypes. Our findings suggest potential interventions targeting CRP-inflammatory markers to reduce breast cancer risk.
BACKGROUND: Immune-related etiologic pathways that influence breast cancer risk are incompletely understood and may be confounded by lifestyles or reverse causality. Using a Mendelian randomization (MR) approach, we investigated the potential causal relationship between genetically elevated C-reactive protein (CRP) concentrations and primary invasive breast cancer risk in postmenopausal women. METHODS: We used individual-level data obtained from 10,179 women, including 537 who developed breast cancer, from the Women's Health Initiative Database for Genotypes and Phenotypes Study, which consists of five genome-wide association (GWA) studies. We examined 61 GWA single-nucleotide polymorphisms (SNPs) previously associated with CRP. We employed weighted/penalized weighted-medians and MR gene-environment interactions that allow instruments' invalidity to some extent and attenuate the heterogeneous estimates of outlying SNPs. RESULTS: In lifestyle-stratification analyses, genetically elevated CRP decreased risk for breast cancer in exogenous estrogen-only, estrogen + progestin, and past oral contraceptive (OC) users, but only among relatively short-term users (<5 years). Estrogen-only users for ≥5 years had more profound CRP-decreased breast cancer risk in dose-response fashion, whereas past OC users for ≥5 years had CRP-increased cancer risk. Also, genetically predicted CRP was strongly associated with increased risk for hormone-receptor positive or human epidermal growth factor receptor-2 negative breast cancer. CONCLUSIONS: Our findings may provide novel evidence on the immune-related molecular pathways linking to breast cancer risk and suggest potential clinical use of CRP to predict the specific cancer subtypes. Our findings suggest potential interventions targeting CRP-inflammatory markers to reduce breast cancer risk.
Keywords:
Mendelian randomization; breast cancer subtypes by hormone receptor and HER2/neu; exogenous estrogen; genetically driven C-reactive protein; obesity
Authors: Ursula M Schick; Paul L Auer; Joshua C Bis; Honghuang Lin; Peng Wei; Nathan Pankratz; Leslie A Lange; Jennifer Brody; Nathan O Stitziel; Daniel S Kim; Christopher S Carlson; Myriam Fornage; Jeffery Haessler; Li Hsu; Rebecca D Jackson; Charles Kooperberg; Suzanne M Leal; Bruce M Psaty; Eric Boerwinkle; Russell Tracy; Diego Ardissino; Svati Shah; Cristen Willer; Ruth Loos; Olle Melander; Ruth Mcpherson; Kees Hovingh; Muredach Reilly; Hugh Watkins; Domenico Girelli; Pierre Fontanillas; Daniel I Chasman; Stacey B Gabriel; Richard Gibbs; Deborah A Nickerson; Sekar Kathiresan; Ulrike Peters; Josée Dupuis; James G Wilson; Stephen S Rich; Alanna C Morrison; Emelia J Benjamin; Myron D Gross; Alex P Reiner Journal: Hum Mol Genet Date: 2014-09-03 Impact factor: 6.150
Authors: William L Haskell; I-Min Lee; Russell R Pate; Kenneth E Powell; Steven N Blair; Barry A Franklin; Caroline A Macera; Gregory W Heath; Paul D Thompson; Adrian Bauman Journal: Med Sci Sports Exerc Date: 2007-08 Impact factor: 5.411